About PTSD
PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA) , PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.
Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• GlaxoSmithKline
• Pfizer
• Otsuka Pharmaceutical
Other Prominent Vendors
• Azevan Pharmaceuticals
• Baylor Research Institute
• Eli Lilly
• Forest Laboratories
• H. Lundbeck
• Humanetics Pharmaceuticals
• Marinus Pharmaceuticals
• Nanotherapeutics
• Neurocrine Biosciences
• Novartis Pharmaceuticals
• Synchroneuron
• Tonix Pharmaceuticals
Market Driver
• Growing Number of Accidents and Violence Worldwide
• For a full, detailed list, view our report
Market Challenge
• Unavailability of Standard Diagnostic Methods
• For a full, detailed list, view our report
Market Trend
• Rise in Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1 PaxilSeroxat
05.2 Zoloft
06. Introduction
07. PTSD Overview
07.1 Understanding the Disorder
07.2 Etiology and Pathogenesis
07.3 Signs and Symptoms
07.3.1 Re-experiencing Symptoms
07.3.2 Avoidance Symptoms
07.3.3 Arousal Symptoms
07.4 Diagnosis
07.5 Management
07.5.1 Psychotherapy
07.5.2 Pharmacotherapy
07.6 Self-Help Treatment of PTSD
07.7 Epidemiology
07.8 Economic Burden
08. Pipeline Analysis
08.1 Information on Pipeline Candidates
08.1.1 Brexpiprazole
08.1.2 Iloperidone
08.1.3 NBI-77860GSK-561679
08.1.4 At-Ease
08.1.5 PRX-3140
08.1.6 SNC-102
08.1.7 TNX-102 SL
08.1.8 Ganaxolone
08.1.9 SRX251 and SRX246
08.1.10 Doxazosin
08.1.11 pep-EphrinA4
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Market Segmentation by Class of Drug
10.1 Antidepressant Drugs
10.1.1 SSRIs
10.1.2 SNRIs
10.1.3 Tricyclic Antidepressants
10.1.4 MAO Inhibitors
10.2 Anti-anxiety Drugs
10.2.1 Benzodiazepines
10.2.2 Beta-blockers
10.3 Others
10.3.1 Atypical Antipsychotics
10.3.2 Anticonvulsants
10.3.3 Alpha-1 Receptor Antagonists
10.3.4 Alpha-2 Adrenergic Agonists
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and Their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and Their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Analysis 2014
19.2.1 Pfizer
19.2.2 GlaxoSmithKline
19.2.3 Otsuka Pharmaceutical
19.3 Other and Future Prominent Vendors
20. Global PTSD Therapeutics Market: Key Takeaways
21. Key Vendor Analysis
21.1 GlaxoSmithKline
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2014
21.1.4 Business Segmentation by Revenue 2013 and 2014
21.1.5 Geographical Segmentation by Revenue 2014
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Otsuka Pharmaceutical
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2014
21.2.4 Business Segmentation by Revenue 2013 and 2014
21.2.5 Geographical Segmentation by Revenue 2014
21.2.6 Business Strategy
21.2.7 Recent Developments
21.2.8 SWOT Analysis
21.3 Pfizer
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2014
21.3.4 Business Segmentation by Revenue 2013 and 2014
21.3.5 Geographical Segmentation by Revenue 2014
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
22. Other Reports in This Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Events Leading to PTSD
Exhibit 3: Treatment Options for PTSD
Exhibit 4: Prevalence of PTSD among Women in US
Exhibit 5: Global Prevalence of PTSD by Gender
Exhibit 6: Pipeline Portfolio of PTSD Drugs
Exhibit 7: Global PTSD Therapeutics Market 2014-2019 ($ millions)
Exhibit 8: Segmentation of Global PTSD Therapeutics Market by Class of Drug
Exhibit 9: Segmentation of Global PTSD Therapeutics Market by Region 2014
Exhibit 10: Major Drivers of Global PTSD Therapeutics Market
Exhibit 11: Major Challenges in Global PTSD Therapeutics Market
Exhibit 12: Major Trends in Global PTSD Therapeutics Market
Exhibit 13: Global PTSD Therapeutics Market Analysis 2014
Exhibit 14: Pfizer: YoY Growth and Revenue of Zoloft 2010-2014 ($ millions)
Exhibit 15: Pfizer: Revenue of Zoloft by Region 2010-2014 ($ millions)
Exhibit 16: GlaxoSmithKline: YoY Growth and Revenue of Paxil 2010-2014 ($ millions)
Exhibit 17: GlaxoSmithKline: Revenue of Paxil by Region 2010-2014 ($ millions)
Exhibit 18: Global PTSD Therapeutics Market: Key Takeaways
Exhibit 19: GlaxoSmithKline: Business Segmentation by Revenue 2014
Exhibit 20: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 21: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
Exhibit 22: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
Exhibit 23: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 ($ millions)
Exhibit 24: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 25: Pfizer: Business Segmentation by Revenue 2014
Exhibit 26: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 27: Pfizer: Geographical Segmentation by Revenue 2014
